

09/600,786

L1 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2001:592302 CAPLUS

DOCUMENT NUMBER: 135:137336

TITLE: Anandamide derivatives and their therapeutic applications

INVENTOR(S): Raphael, Mechoulam; Yoram, Houminer; Tzviel, Sheskin; Esther, Fride; Joram, Slager

PATENT ASSIGNEE(S): Yissum Research Development Company, Israel

SOURCE: Israeli, 21 pp.

CODEN: ISXXAQ

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
IL 113228	A1	19990922	IL 1995-113228	19950403
PRIORITY APPLN. INFO.:			IL 1995-113228	19950403
OTHER SOURCE(S):	MARPAT	135:137336		

GI



AB Anandamide derivs., such as I [R<sub>1</sub> = H, alkyl; R<sub>2</sub> = alkyl; R<sub>3</sub> = (CH<sub>2</sub>)<sub>m</sub>X, CH(CH<sub>3</sub>)(CH<sub>2</sub>)<sub>m</sub>X, cycloalkyl, benzyl, (CH<sub>2</sub>)<sub>q</sub>NH<sub>2</sub>; X = OH, Me; m, = 0, small integer; n = small integer; q = 1, 3; dashed line = single or double bond], and their optically active isomers were prepared for their use in anti-inflammatory, antiasthmatic, antiglaucoma, antiemetic and analgetic compns. Thus, anandamide derivative II was prepared via a multistep synthetic sequence starting from arachidonic Me ester, Me iodide and ethanolamine. The prepared anandamide derivs. were tested for their binding to the brain cannabinoid receptor CB<sub>1</sub>, and their therapeutic use in anti-inflammatory, antiglaucoma and antiasthma medicines.